Chimeric Therapeutics Advances Cancer Trials and Secures Funding
Company Announcements

Chimeric Therapeutics Advances Cancer Trials and Secures Funding

Chimeric Therapeutics Ltd. (AU:CHM) has released an update.

Chimeric Therapeutics made significant strides in its cell therapy programs, enrolling the first patient in its CHM CDH17 Phase 1/2 trial targeting colorectal and other cancers. The company is also collaborating with partners to expand patient access and manufacturing capabilities. Additionally, Chimeric secured $5 million in capital commitments, signaling strong investor confidence.

For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App